Using PET imaging to study neuroinflammation in depression
Clinical Application of DPA-714 and FDG PET/MRI Imaging in Patients With Depression
This study is testing how inflammation in the brain affects energy use in people with depression to see if there are differences between those who have had multiple episodes and those experiencing it for the first time.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 35 Years to 85 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Dalian Medical University Academic / other |
| Locations | 1 site (Dalian, Liaoning) |
| Trial ID | NCT06565936 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between neuroinflammation and glucose metabolism in patients with depression using advanced PET imaging techniques. It employs two tracers, [18F] DPA-714 and [18F] FDG, to visualize metabolic and neuroinflammatory changes in the brain. The research aims to identify differences in microglial activation and glucose metabolism in specific brain regions between individuals with recurrent and first-episode depression compared to a control group. By understanding these mechanisms, the study hopes to shed light on the pathogenesis of depression.
Who should consider this trial
Good fit: Ideal candidates include adults aged 35-85 with recurrent or first-episode major depressive disorder who meet specific diagnostic criteria.
Not a fit: Patients with significant recent infections, those taking anti-infective drugs, or individuals with uncontrolled diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for depression by elucidating its underlying biological mechanisms.
How similar studies have performed: While the approach of using PET imaging to study neuroinflammation in depression is gaining traction, this specific combination of tracers and methodology is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. For all groups : * No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination * MMSE≥24 points，MOCA≥26 points * No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks * Patients with diabetes had fasting controlled below 9.0mmol/L before the examination * Volunteer to participate in the study and sign the informed consent 2. For Recurrent depression patients: * Meet the Diagnostic criteria for recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * Age 35-85 years old, gender is not limited * HAMD≥8 points 3. For first episode depression Patients: * Gender, age and education level were matched with the recurrent depression group * Meet the Diagnostic criteria for the first episode of depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * HAMD≥8 points 4. For controls: * Healthy people undergoing "DPA-714 or FDG imaging PET/MRI" physical examination in PET/CT room of our hospital * Gender and education level were consistent with both the recurrent depression group and the first-episode depression group * never used any psychotropic drugs * HAMD\<8 points；HAMA\<7 points Exclusion Criteria(for all groups): * Have a history of organic mental disorders or other mental disorders * A family history of hereditary diseases * Persons with mental retardation or dementia * A history of psychoactive substance abuse * Can not cooperate with/complete the psychological examination scale * Previously found serious physical diseases (heart, brain, liver, lung and kidney) * MRI contraindications, abnormalities found in head CT or MRI * A history of drug or alcohol abuse * Have a history of metabolic diseases such as hyperthyroidism, hypothyroidism,and rheumatic diseases * are in the state of pregnancy or breastfeeding
Where this trial is running
Dalian, Liaoning
- The First Affiliated Hospital of Dalian Medical University — Dalian, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Huimin Zhang — The First Affiliated Hospital of Dalian Medical University
- Study coordinator: Huimin Zhang
- Email: huiminzhangxs@163.com
- Phone: +86 18098876233
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.